In the South and Central America pharmaceutical industry, there were 8 M&A deals announced in Q2 2023, worth a total value of $349.7m, according to GlobalData’s Deals Database. The $242.3m minority acquisition of hypera by votorantim was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in South and Central America decreased by 2% in Q2 2023 compared with the previous quarter’s total of $356.9m and fell by 29% as compared to Q2 2022. Related deal volume decreased by 27% in Q2 2023 versus the previous quarter and was 14% higher than in Q2 2022.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Smarter leaders trust GlobalData
Premium Insights Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 - Thematic Intelligence
Premium Insights
The gold standard of business intelligence.
